Valneva SE (NASDAQ:VALN) Sees Significant Growth in Short Interest

Valneva SE (NASDAQ:VALN) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 16,900 shares, an increase of 191.4% from the February 28th total of 5,800 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 57,400 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Valneva stock. Wells Fargo & Company MN lifted its stake in shares of Valneva SE (NASDAQ:VALN) by 14.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 246,766 shares of the company’s stock after purchasing an additional 30,859 shares during the period. Wells Fargo & Company MN owned about 0.30% of Valneva worth $1,079,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 11.39% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on VALN shares. Guggenheim lowered their target price on Valneva from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, March 24th. HC Wainwright reiterated a “buy” rating and set a $17.00 price objective on shares of Valneva in a research note on Friday, March 21st.

Valneva Trading Up 0.1 %

NASDAQ:VALN opened at $7.26 on Friday. The stock has a market cap of $589.95 million, a price-to-earnings ratio of -55.85 and a beta of 1.93. Valneva has a one year low of $3.62 and a one year high of $9.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The business’s 50-day simple moving average is $6.63 and its 200 day simple moving average is $5.61.

Valneva (NASDAQ:VALN) last announced its earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The business had revenue of $56.48 million during the quarter, compared to analyst estimates of $55.64 million. As a group, sell-side analysts predict that Valneva will post 0.13 earnings per share for the current fiscal year.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.